drugset / Trial / NCT00617123
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
Phase 3
Completed
258 enrolled
Merck Sharp & Dohme LLC
Duke Clinical Research Institute · collabThe TIMI Study Group · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
Timeline
- Start
- 2008-07-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorapaxar | Small molecule | 2.5 mg | Oral |